Blue Capital Inc’s Moderna MRNA Stock Holding History

Blue Capital Inc’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,687	Closed	-$289K	–	140
2026 Q1	$289K	Buy	+5,687	New	+$265K	0.19%	85

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Blue Capital Inc's MRNA Position: Q2 2026 in Review

Blue Capital Inc sold out of Moderna (MRNA) in Q2 2026, closing a stake of 5,687 shares — an estimated $289K sold.

Blue Capital Inc first reported a position in MRNA in Q1 2026 and held it in 1 quarter. The position peaked at $289K in Q1 2026. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Blue Capital Inc reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Blue Capital Inc sold 5,687 Moderna shares in Q2 2026, an estimated $289K.
Blue Capital Inc first reported a position in Moderna in Q1 2026 and held it in 1 quarter.
Blue Capital Inc's Moderna position peaked at $289K in Q1 2026.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Blue Capital Inc's 13F filing for Q2 2026, filed 11 Aug 2026.